Phase I Double-Blind, Placebo-Controlled Trial of 27 mg Dolcanatide (SP‐333) to Demonstrate Colorectal Bioactivity in Healthy Volunteers
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 08 Feb 2019
At a glance
- Drugs Linaclotide (Primary)
- Indications Constipation; Irritable bowel syndrome; Visceral pain
- Focus Pharmacokinetics
- 30 Jan 2019 Status changed from recruiting to active, no longer recruiting.
- 24 Sep 2018 Planned End Date changed from 1 Feb 2019 to 15 Apr 2019.
- 24 Sep 2018 Planned primary completion date changed from 1 Feb 2019 to 15 Apr 2019.